ADDvise Group contemplates issuance of subsequent senior secured bonds

21-11-2022   Regulatory press release

ADDvise Group AB (publ) has mandated Pareto Securities AB to arrange a series of fixed income investor meetings starting on 22 November 2022. Subject to inter alia market conditions, a subsequent bond issue of SEK 150 million under the company's existing senior secured bond loan with ISIN SE0015222088 (the "Bonds") may follow. The subsequent bond issue is fully subscribed based on substantial pre-commitments and indications from certain investors.

The net proceeds from the contemplated subsequent bond issue will be used to part-finance the acquisition of CliniChain Holding B.V. or any other acquisition replacing the acquisition of CliniChain Holding B.V.

In connection with the contemplated subsequent bond issue, the company will request approval from holders of the Bonds for certain amendments to the terms and conditions of the Bonds in order to inter alia permit the contemplated subsequent bond issue. Additional information pertaining to the written procedure is set out in a separate press release as well as in the relevant notice of written procedure.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se

Hanna Myhrman, General Counsel
+46 709-82 92 23
hanna.myhrman@addvisegroup.se

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 21 November 2022 at 17:45 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The Group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expanding the business – both geographically and product-wise. ADDvise Group’s shares are listed on Nasdaq First North Premier Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

 

 

 

Latest press releases

ADDvise acquires CliniChain Holding B.V.

Regulatory

ADDvise Group AB has today entered into a share purchase agreement with the owners of CliniChain Holding B.V. (“CliniChain”) regarding the acquisition of all the outstanding shares of CliniChain in accordance with the letter of intent communicated via a press release dated September 6, 2022. Closing of the acquisition takes place no later than December…

ADDvise receives order worth USD 1.7 million

Regulatory

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from BioGeneric Pharma, a leading factory in biotechnology based in Cairo, Egypt. The order is worth approximately USD 1.7 million. The order is an add-on-project in the ongoing project between the parties regarding design, supply, and commissioning of clean room environment to be used…

ADDvise Group successfully places subsequent senior secured bonds of SEK 150 million at par

Regulatory

ADDvise Group AB (publ) ("ADDvise" or the "Company") announces today that the Company has successfully placed a subsequent senior secured bond issue (the “Subsequent Bond Issue") in an amount of SEK 150 million under the Company’s existing senior secured bond framework with ISIN SE0015222088. Following completion of the Subsequent Bond Issue, the outstanding amount under…